IONIS PHARMACEUTICALS INC
TRYNGOLZA
severe hypertriglyceridemia
Resolved
188days ago
Phase 3 readout · Dec 31, 2025
What's at stake
Phase 3 trial results for TRYNGOLZA in severe hypertriglyceridemia are due Dec 31, 2025. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“TRYNGOLZA demonstrated a statistically significant reduction in fasting triglycerides of 49%-63% (50 mg) and 55%-72% (80 mg) compared to placebo at six months.”